Larimar Therapeutics (LRMR) Other Non-Current Assets (2013 - 2025)
Larimar Therapeutics (LRMR) posted Other Non-Current Assets of $523000.0 for Q4 2025, down 13.7% on a QoQ basis from $606000.0 in Q3 2025, and down 12.25% year-over-year from $596000.0 in Q4 2024.
Larimar Therapeutics (LRMR) Other Non-Current Assets (2013 - 2025) Analysis & Trends
Larimar Therapeutics' Other Non-Current Assets history runs 13 years deep, the most recent figure standing at $523000.0 for Q4 2025.
- Quarterly Other Non-Current Assets fell 12.25% year-over-year to $523000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $523000.0 (down 12.25% YoY) and the FY2025 annual result came in at $523000.0, down 12.25% from the prior year.
- Other Non-Current Assets was $523000.0 for Q4 2025 at Larimar Therapeutics, down from $606000.0 in the prior quarter.
- Across five years, Other Non-Current Assets topped out at $1.3 million in Q2 2021 and bottomed at $523000.0 in Q4 2025.
- A 5-year average of $913400.0 and a median of $674500.0 in 2021 frame the typical range for Other Non-Current Assets.
- Annual changes were most pronounced in 2021 — Other Non-Current Assets soared 6150.0% — and 2025, when it sank 58.1%.
- Larimar Therapeutics' Other Non-Current Assets stood at $1.3 million in 2021, then changed by 0.0% to $1.3 million in 2022, then changed by 0.0% to $1.3 million in 2023, then slumped by 55.49% to $596000.0 in 2024, then dropped by 12.25% to $523000.0 in 2025.
- Business Quant data shows LRMR's Other Non-Current Assets at $523000.0 in Q4 2025, $606000.0 in Q3 2025, and $561000.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | 1.02 Mn |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | 60,000.00 |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 104.24 Mn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 1.26 Bn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | 2.13 Bn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | 289.41 Mn |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | 124.00 Mn |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | 14.48 Mn |
| 10 | Larimar Therapeutics | 37.00 Mn | -99.85 Mn | - | 523,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 523,000.00 |
| Sep 30, 2025 | 606,000.00 |
| Jun 30, 2025 | 561,000.00 |
| Mar 31, 2025 | 582,000.00 |
| Dec 31, 2024 | 596,000.00 |
| Sep 30, 2024 | 1.34 Mn |
| Jun 30, 2024 | 1.34 Mn |
| Mar 31, 2024 | 678,000.00 |
| Dec 31, 2023 | 1.34 Mn |
| Sep 30, 2023 | 634,000.00 |
| Jun 30, 2023 | 644,000.00 |
| Mar 31, 2023 | 1.34 Mn |
| Dec 31, 2022 | 1.34 Mn |
| Sep 30, 2022 | 643,000.00 |
| Jun 30, 2022 | 1.34 Mn |
| Mar 31, 2022 | 668,000.00 |
| Dec 31, 2021 | 1.34 Mn |
| Sep 30, 2021 | 671,000.00 |
| Jun 30, 2021 | 1.34 Mn |
| Mar 31, 2021 | 750,000.00 |